Loading
Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.
Ajai Chari was principal investigator and first author of MonumenTAL-1, the trial that established the GPRC5DxCD3 bispecific talquetamab in relapsed myeloma and validated a target beyond BCMA. He has led studies of subcutaneous daratumumab, selinexor and real-world outcomes in myeloma and directs the myeloma programme at UCSF after many years at Mount Sinai.
Shares CD38, CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tags myeloma, bispecific.
Shares MonumenTAL-1, GPRC5D, Multiple myeloma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
Shares Bispecific antibodies, T-cell engagers (bispecific), Multiple myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/